Philip Stein Announces Results from Clinical Trial Showing Improved Sleep Quality through Natural Frequency Technology
News Oct 26, 2009
Philip Stein, the manufacturer of Philip Stein timepieces with frequency technology, announced the results from a clinical study designed to determine the beneficial effects of natural frequency technology incorporated in the company’s watches.
The study reports that individuals who participated in the study, felt more refreshed in the morning, and experienced more vivid dreams in their sleep. In addition the participants fell asleep faster when wearing the Philip Stein watch, but woke up less during the night, then those wearing a watch without the natural frequency technology inside.
The study was overseen by Dr. Michael Breus, PhD, a board certified sleep specialist and a noted authority on sleep and sleep issues. The announcement was made today by Will Stein, President of Philip Stein.
“Over time we received numerous testimonials from people wearing Philip Stein watches reporting about their positive experiences with regards to sleep. It was important for us to back up these anecdotal testimonials through a clinical study and to show the beneficial effects of natural frequency technology in our watches,” said Will Stein. “We engaged Dr. Breus to confirm what we’ve heard from our customers, that Philip Stein watches are an asset to people’s well-being and provide a natural alternative to improve sleep quality.”
PHILP STEIN commissioned NeuroTrials Research, an independent clinical trials organization, to conduct a Randomized, Double Blind, Placebo Controlled study. The subjects were both male and female, who were poor sleepers and have reported unrefreshing sleep for at least the past 3 months, and did not have a serious medical or psychological condition. Each of the study participants was given a watch, at two different times, half of which contained the frequency technology, half that did not. Study participants and researchers did not know who had on the active watches and who did not.
Highlights of the results for people who responded to the frequency technology (96% showed some positive response on at least one of the following variables) include:
Feeling Refreshed: When subjects wore the watch only during the day, 43% of people who responded reported feeling refreshed in the morning vs. when they wore a watch without the technology inside.
Time to Fall Asleep: When subjects wore the watch only during the day, 47% of people who responded reported falling asleep faster vs. when they wore a watch without the technology inside.
Total Sleep Time: When subjects wore the watch only during the day, 39% of people who responded reported falling asleep faster and sleeping more minutes vs. when they wore a watch without the technology inside.
Pleasant Dreams: When subjects wore the watch only during the day, 52% of people who responded reported dreaming was more pleasant that night vs. when they wore a watch with no technology inside.
“I am excited to work with a company like Phillip Stein who is committed to learning more about the science behind their unique and effective technology, which has clear benefits for sleep and health,” said Dr. Breus.
Dr. Breus is a Clinical Psychologist and a Diplomate of the American Board of Sleep Medicine. He was one of the youngest people to have passed the Board at age 31 and has a specialty in Clinical Sleep Disorders and Neuropsychological Testing. He is one of only 163 doctors in the world with his credentials and distinction. The study data is currently in the process of being submitted for peer-reviewed journal publication.
Huntsman Cancer Institute Joins National Clinical Trial Targeting AMLNews
Huntsman Cancer Institute (HCI) at the University of Utah (U of U) has been selected to participate in the Beat AML Master Trial, an innovative clinical trial sponsored by The Leukemia & Lymphoma Society (LLS). The clinical trial is testing several new targeted therapies for the treatment of patients with acute myeloid leukemia (AML). HCI is the only facility in the Mountain West offering this trial to AML patients.READ MORE
Study Extends Potential of Personalized Cell-based ImmunotherapiesNews
New methods developed for the study could be applied to devise personalized, cell-based immunotherapies for epithelial ovarian cancer or other types of tumorsREAD MORE